EBGene trial: patient preselection outcomes for the European GENEGRAFT ex vivo phase I/II gene therapy trial for recessive dystrophic epidermolysis bullosa
Integrin α3β1 Is a Key Regulator of Several Protumorigenic Pathways during Skin Carcinogenesis
1 April 2021

Br J Dermatol. 2020 Mar;182(3):794-797. doi: 10.1111/bjd.18559. Epub 2019 Nov 27. PMID: 31557321.

EBGene trial: patient preselection outcomes for the European GENEGRAFT ex vivo phase I/II gene therapy trial for recessive dystrophic epidermolysis bullosa

Authors: S Gaucher 1 2 3S M Lwin 4M Titeux 1A Abdul-Wahab 4N Pironon 1 2A Izmiryan 1 2S Miskinyte 1C Ganier 1S Duchatelet 1J E Mellerio 4E Bourrat 5J A McGrath 4A Hovnanian 1 2 6

Affiliation:

  1. INSERM UMR 1163, Laboratory of Genetic Skin Diseases, Imagine Institute, Paris, France.
  2. University Paris Descartes-Sorbonne Paris Cité, Paris, France.
  3. Service de Chirurgie Générale, Plastique et Ambulatoire, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France.
  4. St John’s Institute of Dermatology, King’s College London, London, U.K.
  5. Department of Dermatology, Assistance Publique-Hôpitaux de Paris, Hôpital Saint-Louis, Paris, France.
  6. Department of Genetics, Assistance Publique-Hôpitaux de Paris, Necker Hospital for Sick Children, Paris, France.

Abstract:

No abstract available (Letter to the editor)

Download: https://academic.oup.com/bjd/article/182/3/794/6731517?login=true